trending Market Intelligence /marketintelligence/en/news-insights/trending/SYQWHIRApW8akeXinMxqNw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Karo Pharma to acquire 10 products from Leo Pharma for €90M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Karo Pharma to acquire 10 products from Leo Pharma for €90M

Karo Pharma AB (publ) agreed to acquire anti-hemorrhoid and dermatology products from Danish pharmaceutical company LEO Pharma Inc. for €90 million.

The products to be acquired include four anti-hemorrhoid — Sheriproct, Doloproct, Neriproct and Ultraproct — and six dermatology products — Ultrabas, Ultralip, Ultraphil, Ultrasicc, Neribas and Ultralan.

The anti-hemorrhoid products contribute the majority of the acquired portfolio's net sales.

Karo Pharma said it intends to divest Neriproct, which is only marketed in the Japanese market, since it is outside the company's focus market.

While the estimated turnover of the acquired portfolio is €35 million for 2019, Karo Pharma expects an increase in the running costs of about 10 million Swedish kronor per year following the acquisition.

The transaction is subject to customary competition authority approvals and is expected to complete by the end of the first quarter of 2020. Karo pharma will finance the acquisition with new loans from SEB and Swedbank as well as from cash on hand.

Stockholm-based Karo Pharma develops and markets prescription pharmaceuticals, over-the-counter products, medical devices and other healthcare-related products for pharmacies.

As of Dec. 20, US$1 was equivalent to 9.42 Swedish kronor.